Efficacy Study to Evaluate B-Lock™ as an Antimicrobial Lock Solution in Dialysis Patients With a CVC

Inclusion Criteria: * Male or female patients age 18 to 80 years, inclusive. Patients, age 81 to 85 years, inclusive, may be included on a case-by-case basis if their health status is determined to be stable after consultation with the Medical Monitor. * Patients with end-stage renal disease receiving hemodialysis via CVC. * Patients must be expected to receive hemodialysis through a direct or cuffed, tunneled dual lumen catheter or 2 cuffed, tunneled single lumen catheters for a minimum of 45 catheter-days after Day 1. * Patients must have been receiving dialysis for a minimum of 6 dialysis sessions at the study center dialysis clinic prior to the signing of the Informed Consent Form (ICF). * Patients must have received dialysis at their prescribed blood flow rate (+/- 10%) for at least 2 consecutive dialysis sessions prior to signing the ICF. * Patients must have 2 screening pre-pump arterial pressure measurements (collected during the first 20 minutes of dialysis) that differ by less than or equal to (≤) 20 mmHg at 2 consecutive dialysis sessions when receiving dialysis at their prescribed blood flow rate (+/- 10%) prior to randomization. Exclusion Criteria: * Clinical signs and/or symptoms of a local or systemic infection within 14 days prior to Day 1. * Evidence of infection of the catheter exit site/tunnel within 14 days prior to Day 1. * Patients who have received systemic antibiotics within 14 days prior to Day 1. * History of fever (T \> 37.5°C) or chills within 14 days prior to Day 1. * An occluded catheter (blood flow inadequate for dialysis) or a catheter that required thrombolytic treatment within 14 days prior to Day 1. * A catheter coated or impregnated with an antithrombotic, antimicrobial or antiseptic agent, including heparin. * A catheter coated or impregnated with an antithrombotic, antimicrobial or antiseptic agent, including heparin. * Catheters that are deemed by their manufacturers to be incompatible with alcohol-containing solutions. These include, but are not limited to: 1. Angiodynamics - LifeJet® VP VascPak Catheter. 2. Angiodynamics - Schon™ Chronic Hemodialysis Catheter. 3. Angiotech - Hemostream™ Chronic Dialysis Catheter. 4. Bard - all Bard Catheters. * The use of TEGO® or TEGO-like catheter caps. Patients may be switched to standard catheter caps in order to participate in this study. * Patients with a known or documented allergy to TMP or TMP-containing drugs, ethanol, ethylene diamine tetraacetic acid (EDTA), propylene glycol and/or glycerin. * Patients with a history of heparin-induced thrombocytopenia or in whom the use of heparin is contraindicated. (Note: If the use of heparin is restricted for only a specified period of time, the patient may be enrolled at a later date when the use of heparin is no longer contraindicated.) * Evidence of acute/ongoing hepatic injury (alanine aminotransferase \[ALT\] \> 300 IU/L) or chronic hepatic insufficiency (Total bilirubin \> 2.0 mg/dL and/or albumin \< 3.0 g/dL during Screening or within 30 days prior to Screening). Note: A patient whose albumin level is low solely due to nephrotic syndrome may be enrolled (with Medical Monitor approval) if the albumin level has been stable for at least 3 months prior to ICF signature. * Patients who the Investigator believes have a prognosis for survival of less than 3 months.